Statements (17)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:AuryxiaIndication |
treatment of hyperphosphatemia in chronic kidney disease
treatment of iron deficiency anemia in chronic kidney disease |
| gptkbp:focusesOn |
renal disease treatments
|
| gptkbp:foundedIn |
1998
|
| gptkbp:founder |
Michael S. Weiss
|
| gptkbp:headquartersLocation |
gptkb:Boston,_Massachusetts,_United_States
|
| https://www.w3.org/2000/01/rdf-schema#label |
Keryx Biopharmaceuticals
|
| gptkbp:industry |
gptkb:biotechnology
|
| gptkbp:mergedInto |
gptkb:Akebia_Therapeutics
2018 |
| gptkbp:notableProduct |
Auryxia
|
| gptkbp:stockSymbol |
KERX
|
| gptkbp:tradedOn |
gptkb:NASDAQ
|
| gptkbp:website |
www.keryx.com
|
| gptkbp:bfsParent |
gptkb:Perifosine
|
| gptkbp:bfsLayer |
7
|